A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms OAsIs
- 10 Aug 2017 Planned number of patients changed from 33 to 48.
- 10 Aug 2017 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 10 Aug 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Apr 2018.